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Abstract  
Introduction: Liver fibrosis is common among HIV-infected patients. Risk factors vary by 
location. Understanding this variation may inform prevention strategies. We compared the 
prevalence and correlates of liver fibrosis among HIV-infected patients attending care clinics 
in Uganda. 
Methods:  Cross sectional study involving 2030 HIV-infected patients attending care clinics 
in urban and rural Uganda. Liver fibrosis was defined as liver stiffness measurement (LSM) 
>7.1KPa. Proportions and correlates of liver fibrosis were assessed and compared using 
logistic regression stratified by gender and site.  
Results: Prevalence of liver fibrosis was higher among participants in the rural clinic (15% Vs 
11%; p0.017). History of tobacco use (urban p0.022; rural p0.035) and serologic evidence of 
hepatitis C infection (HCV) (urban p0.028; rural p0.03) was associated with liver fibrosis in all 
men. Elevated liver transaminases (urban p0.002; rural p0.028) and increasing age (urban 
p0.008; rural p0.052) were risk factors among all women. Tobacco use among women was 
only a risk factor in those attending the rural clinic (p0.003) and detectable HIV viral load 
(p0.002) for men in the urban clinic.   
Conclusion: Liver fibrosis is prevalent among HIV-infected persons in Uganda. HIV viral 
suppression and avoiding tobacco may be strategies to prevent liver fibrosis and cancer risk. 
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Introduction: With improved HIV/AIDS care and management, HIV-infected persons now 
live long enough to experience other non-HIV related causes of disease or death, such as 
liver disease [1]. Liver disease is the second leading cause of death among HIV infected 
persons [2]. Risk factors for liver disease have transitioned in the era of anti-retroviral 
therapy (ART), with less opportunistic infections and more co-morbid diseases and 
infections being the drivers for liver disease [3, 4]. Viral hepatitis is the major risk factor for 
liver disease in this population given that the routes of transmission are shared and progress 
to ensuing complications in comparison to the general population is faster. In the 
background of HIV there is increased viral replication of hepatitis B and reduced viral 
shedding of hepatitis C [5]. Other risk factors include direct (infection of all types of liver 
cells by the HIV with premature death) and indirect (cytokine driven mechanisms 
stimulating increasing collagen formation) effects of chronic HIV infection, toxicity from long 
term exposure to drugs including ART, exposure to aflatoxin, harmful use of alcohol and 
metabolic conditions that predispose to elevated blood lipids [3, 4, 6-8]. Urbanization does 
influence the distribution of these risk factors geographically on a global scale and even 
within specific countries and consequently influences distribution of liver disease. For 
example, the disparity in the distribution of risk factors such as viral hepatitis, obesity, use of 
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alcohol and tobacco within the country has been demonstrated from various separate 
studies[9, 10]  
Chronic inflammation of the liver resulting from any one risk factor develops into liver 
fibrosis. Liver fibrosis is the primary risk factor for complicated liver disease, notably 
cirrhosis and or hepatocellular carcinoma[11]. Most studies on aetiology of liver fibrosis 
have been undertaken in western populations[12]. The few studies done in sub Saharan 
Africa (SSA) were mainly conducted before the era of ART rollout,  demonstrating most of 
the causes as opportunistic conditions resulting from a deprived immune state [13, 14]. The 
few other studies done in the era of ART rollout focused on select populations, for example 
hepatitis B/HIV co-infected patients,  using non-invasive methods with low accuracy for 
assessment of liver fibrosis [15-18]. HIV-infection accelerates progression of liver fibrosis to 
complicated disease.  Sub Saharan Africa harbors 80% of the global burden of HIV/AIDS and 
would be most likely to experience an epidemic of complications of liver fibrosis if no 
preventive measures are taken [19, 20]. The same region has limited expertise and or 
advanced therapeutic options such as liver transplant, rendering tertiary management of 
complications of liver fibrosis costly. Presently the region has at least a decade worth of 
experience on ART and improved longevity of people living with HIV/AIDS. It would 
therefore be important to evaluate for other risk factors, not limited to viral hepatitis using 
relatively more accurate diagnostics to understand the differences in burden and 
distribution of drivers for liver fibrosis in resource limited settings informing tailored cost-
effective prevention strategies. Therefore, we undertook a study to determine and compare 
the prevalence and factors associated with liver fibrosis among HIV infected patients 
routinely presenting to a rural primary and an urban, tertiary care clinic in Uganda.  
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Study methods  
This was a cross sectional study based on pooled data from two different studies involving 
HIV-infected persons aged ≥18 years attending care clinics. The study in the rural General 
Population Clinic (rural clinic), a primary care clinic involved active data collection and that 
at the urban tertiary clinic, the Adult Infectious Diseases Clinic (urban clinic) in Kampala, 
Uganda was secondary data analysis of previously collected data for a prospective study 
looking at the prevalence and progression of pre-malignant cirrhosis. Both the rural and 
urban clinic are well described  elsewhere [21-23]. Both the rural and urban studies were 
conducted between January 2015 and December 2017.   
Participant enrollment procedure 
Participants from the rural clinic were actively mobilized from within their households in 
their respective villages using field research staff having been identified as HIV sero-positive 
from a previous sero-survey conducted in 2011. Field research staff using residence 
information retrieved from the previous survey made physical visits to communicate 
information about the study and obtain screening consent. We sampled from all 23 villages 
that were within a 10km radius from the GPC clinic. A total of 522 of 8000 (6.5%) persons 
were identified from the 2011 sero-survey as HIV-positive. Those that still resided within the 
villages and were able to be located and provided initial consent were provided an 
appointment date to come to the research clinic to provide informed consent for all study 
procedures (Figure 1). Adults with no documented or known history of liver disease, no 
history of medical implants and provided informed consent were eligible to participate in 
the study. Pregnant women were not eligible to participate in the study. Participants from 
the urban clinic were selected from a dataset of an on-going study, the HIV Hepatocellular 
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Carcinoma in Uganda (H2U) study that aims to determine the Prevalence and progression of 
pre-malignant cirrhosis. The H2U study enrolled HIV-infected adults who provided informed 
consent to study procedures, including liver fibrosis measurement and laboratory testing. 
Pregnant women, persons with medical implants and persons with known history of liver 
disease were excluded from participation. 
Study procedures 
Questionnaire: A structured interviewer administered questionnaire was used for both 
studies to capture social-demographic information on age, gender and self-reported use of 
alcohol, tobacco and herbal medicines. For the participants in the rural clinic clinical records 
were retrieved to inform on ART use, duration and HIV viral load testing where available. In 
the event that these records were not captured in participants’ clinical records, we relied on 
self-reported information regarding information on when they started ART and how long 
they have been on therapy. ART related information for the participants at the urban clinic 
was retrieved from their clinical records, including similar information of duration of use of 
ART and HIV viral load. 
Anthropometry: Height and weight measurements were taken for participants from both 
clinics. Height and weight were measured using a Seca Leicester stadiometer to the nearest 
0.1 cm and a Seca 761 mechanical scale to the nearest 1 kg, respectively. Participants’ height 
and weight measurements were used to compute a body mass index (BMI) for each 
participant. BMI was calculated as weight (kg)/height (m)2. Participant categorization using 
BMI was as follows; BMI≤18.5 ‘underweight’, BMI 18.5-24.9 ‘normal weight’, BMI 25-29.9 
‘overweight’ and BMI ≥30 ‘obese’. 
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Blood sample processing: Participants from both clinics were bled under aseptic conditions 
for the purposes of serology (hepatitis B&C) and liver function testing. Blood samples for the 
participants from the rural clinic were transported within same day under suitable 
conditions to the Central Diagnostic Laboratory Services (CDLS) at the UVRI/MRC Uganda 
Research Unit Campus in Entebbe. The CDLS is an ISO certified laboratory that processes 
varied volume of samples from multiple on-going research studies. Hepatitis B serology 
(HBV) testing was performed using the Hepanostika® (HBsAg) ultra-confirmatory test 
(BioMérieux SA, Marcy l'Etoile, France). Hepatitis C (HCV) antibody testing was done using a 
4th generation ELISA test (Innotest HCV Ab IV®). Samples from the participants at the urban 
clinic were processed at the same premise as the clinic at the Infectious Diseases Institute in 
the Makerere University John Hopkins University (MUJHU) laboratory, a CAP certified 
laboratory. Hepatitis B serology was performed using an enzyme immunoassay (Monolisa 
HBsAg Ultra 3; Bio-Rad). Hepatitis C antibody testing was done using 3rd generation enzyme 
immunoassay (Bio-rad  Monolisa Anti-HCV PLUS).   
Transient elastography: Liver stiffness measurements (LSM) were taken using Fibroscan® 
Echosens for participants at both clinics. At both clinics the machine was operated by skilled 
personnel, taking 10 valid readings with accuracy of 60% and interquartile range less than 
30%. The median of these 10 readings was what was considered as the final result for the 
liver stiffness and represented in kilo Pascals (KPa). The Fibroscan at the rural clinic only had 
an M-probe, whereas the Fibroscan at the urban clinic had both an M and XL probe, the 
latter appropriate for persons with a BMI≥30. 
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Data Analyses 
The study data was stratified by clinic location because of the differences in the distribution 
of some risk factors for liver fibrosis as shown by other studies done in-country[24, 25]. The 
data was also stratified by sex to control for effect modification based on prior evidence of 
similar studies in rural Uganda and to account for difference in choice of certain risky 
lifestyle habits dictated by gender[26-28]. The outcome liver fibrosis was assessed as a 
binary outcome defined as LSM >7.1KPa, a cutoff similar to prior studies for purposes of 
comparison and also in correspondence to stage F2 and above of the METAVIR staging for 
liver fibrosis for most of the common causes of liver disease [26]. Proportions were used to 
describe socio-demographic, anthropometric and clinical characteristics by clinic site. The 
prevalence of liver fibrosis was presented as a proportion for both study sites and compared 
using a chi square test. The study population identified with liver fibrosis was stratified by 
clinic site and further described using proportions on the socio-demography and clinical 
characteristics and comparison by clinic population made using chi-square test. 
To determine factors associated with liver fibrosis, univariate analysis was conducted for 
each risk factor. Factors with a p-value of 0.15 and less were considered as significant at this 
initial stage and used to build the multi-variate model. Risk factors found to be insignificant 
at univariate analysis and yet known to cause liver fibrosis were retained in the multi-variate 
model. Logistic regression was then conducted and explanatory variables with a p-value ≤ 
0.05 were considered as significant. Analyses were performed using STATA 12 statistical 
package. 
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Patient Consent Statement 
The study was conducted in accordance with the principles of the Declaration of Helsinki. 
Study approval for the rural based study was given by the Uganda Virus Research Institute 
(GC/127/15/04/503 & GC/127/16/05/503), the School of Medicine Research Ethics 
Committee (SOMREC) (#REC REF 2017-165) and the Uganda National Council of Science and 
Technology (UNCST) (HS 1794 & ADM 154/212/01) research ethics committees. The H2U 
urban based study was approved by the SOMREC (REF 2015-149), UNSCT (HS 1984) and the 
John Hopkins Medical Institutes Review Board (IRB 00086055).  Written informed consent 
was obtained from all study participants for study participation, sample collection and 
access to medical records. 
Results 
Table 1 shows the characteristics of the 2030 HIV-infected study participants attending the 
urban and rural clinics. The number of participants attending the urban and rural clinics 
were 1703 and 327 respectively. The majority (60%) of the study participants were female. 
The gender and mean age (urban population mean age was 44 years; rural population mean 
age was 45 years) were similar between the two clinics. The age distribution between the 2 
clinics differed with an older demographic attending the urban clinic. Participants from the 
urban clinic had been on ART for a longer duration than participants attending the GPC clinic 
and had better HIV viral load suppression rates (10 years vs 4 years p0.001; 97%vs 77% 
p<0.001 respectively). Chronic HBV was nearly three times more prevalent among 
participants attending the urban clinic (11% vs 4%; p<0.001), but there was no difference in 
the serological prevalence of HCV between participants attending both clinics. Participants 
in the urban clinic were more overweight and or obese (p<0.001). Participants attending the 
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rural clinic had a higher proportion of having ever consumed alcohol (56% vs 43%; p<0.001); 
of tobacco (23% vs16%; p0.002) and herbal medicine (27%vs20%; 0.007). Liver fibrosis was 
significantly more prevalent among participants attending the rural clinic (15% vs 11%; 
p0.017) and even when stratified by gender, both male and female participants from the 
rural clinic had higher prevalence of liver fibrosis than their counterparts in the urban clinic 
(Fig 2). 
The 224 study participants identified with liver fibrosis from both clinics were similar in 
gender and mean age distribution and proportion of ART coverage (Table 2). Participants 
from the rural clinic identified with liver fibrosis were more likely to have ever used tobacco 
(39% vs 21%; p0.009), have less duration on ART (3years vs 10yrs; p<0.001) and have 
detectable HIV viral loads (24% vs 4%; p<0.001). On the other hand, participants at the 
urban clinic identified with liver fibrosis were more likely to be overweight and obese 
(p0.004) and had seven times higher prevalence of chronic HBV co-infection (14% vs 2%; 
p0.001). The prevalence of HCV and the proportional use of alcohol was similar in both 
populations from both clinics.   
On assessing for the factors associated with liver fibrosis by gender and locality based on 
clinic location, we found history of tobacco use and serologic evidence of HCV to be 
common risk factors among men from both clinics (Table 3). Men from both clinics who had 
ever used tobacco had nearly twice the odds of presenting with liver fibrosis and those that 
tested positive for HCV had three times the odds of having liver fibrosis (OR 3.1; p0.028 
urban participants; OR 3.5; p0.028 rural participants). Risk factors unique to men attending 
the urban clinic were increasing age (OR 1.3; p0.008), detectable HIV viral load (OR 2.3; 
p0.002) and elevated liver transaminases (OR 2.2; p0.002). Common factors associated with 
liver fibrosis among female participants from both clinics (Table 4) included elevated liver 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa483/5922323 by guest on 02 N
ovem
ber 2020
Ac
ce
pte
d M
an
us
cri
pt
transaminases (OR2.3; p0.002 urban participants; OR2.4; p0.028 rural participants) and 
increasing age (OR1.3; p0.008 urban participants; OR1.3; p0.052 rural participants). History 
of tobacco use as a risk factor unique to female participants in the rural clinic was associated 
with three times the odds of having liver fibrosis.  
Discussion  
The prevalence of liver fibrosis among HIV-infected patients attending care clinics both in 
urban and rural Uganda is high and significantly higher among those attending the rural care 
clinic. The prevalence of liver fibrosis among HIV-infected persons attending the rural care 
clinic remains similar to that reported in a previous study (15% vs 17%) done at a time when 
ART access was limited[26]. Studies done elsewhere within SSA have reported similar range 
in prevalence of liver fibrosis among HIV-infected persons ranging between 2% to 24% 
depending on the study population and technique used [15-17, 29, 30].  Among western 
populations the prevalence of liver fibrosis among HIV-infected patients is similar to findings 
of our study and other studies in SSA with estimates of between 16-29% [20]. Anti-retro 
viral therapy has been demonstrated to reduce risk of liver fibrosis via adequate viral 
suppression [8, 31]. In resource limited settings, roll out of HIV care programs started in the 
urban settings long before their initiation within hard to reach areas [23]. Timing of rollout 
impacts the ART experience and consequently infection control. In this study the mean 
duration of ART was longer among the participants in the urban clinic (10years vs 4years) 
and a higher proportion had controlled HIV infection.  Differences in these HIV related 
factors may play a significant role in the observed difference of the burden of liver fibrosis 
observed between these two populations.  
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Tobacco use was a common risk factor regardless of locality or gender. Tobacco is a 
carcinogen that increases risk for HCC and has been documented to compromise the cancer 
surveillance system of the body [32]. Other literature has also demonstrated smoking as an 
independent risk factor for liver fibrosis [33, 34].  Among men from both localities, HCV was 
identified as a common risk factor for liver fibrosis. The transmission routes for HCV are not 
fully understood within SSA; however, established transmission routes from other studied 
populations are mainly associated with high risk behavior common among men[35]. This 
may explain why HCV was a risk factor among men and not women in this study although 
we did not assess for risk behavior such as risky sexual behavior, intravenous drug abuse or 
other practices like tattooing. Chronic HBV was not associated with severe liver disease 
among both populations in either clinic.  The current ART first line therapy in Uganda 
includes two drugs with activity against HBV tenofovir and lamuvidine, the combination of 
which reduces chances of drug resistant HBV infection.  Elevated liver transaminases 
although shown as an associated factor of liver fibrosis, may be a marker of disease severity 
as demonstrated by other studies [36-39].  
A considerable proportion of our study participants were using herbal medicines but we did 
not identify herbal medicines as a risk factor. Previous studies conducted in rural Uganda 
found an association between liver fibrosis and consumption of herbal medicines [40].Given 
that the earlier studies were conducted in a time of relatively limited ART access, it is 
probable that HIV-infected persons resorted to alternate remedies of therapy. It is also 
probable that they consumed them in large quantities and for long durations posing a risk of 
liver injury. Presently there is consorted effort to regulate the production of herbal 
medicines in the country to ensure their safety for human use [41, 42]. Some herbal 
medicines possess anti-fibrotic properties although there remains limited knowledge of the 
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whole scope of their action [43]. Although alcohol abuse is a well-documented risk factor for 
liver disease, we on the contrary found it to be a protective factor only among the 
participants in the urban clinic. Given the well-developed and consistent counselling services 
given to patients at the urban clinic (including substance abuse), it may be possible that 
there exists a counter compensatory behavior adopted by these persons and not necessarily 
the effect of alcohol that could not be accounted for by our study. We also acknowledge 
that its possible it was under reported because most persons will provide socially acceptable 
responses. 
We acknowledge that this study had several limitations. We also did not assess for other 
possible explanatory variables for the proportion of liver fibrosis we observed, such as, 
presence of schistosomiasis that is very common in this setting, co-administered drugs that 
are toxic to the liver such as anti-tuberculous drugs. This study does not account for the 
prior exposures over the life course of the participants. Thus we did not take into account 
the impact of those early exposures like migration history on the impact of the development 
of liver fibrosis. The urban study population was from a tertiary care unit and may not be 
very representative of the wider population of HIV-infected persons in urban Uganda. We 
did not assess for HBV viral load and used serological marker for HCV which is not 
necessarily a marker for active infection and has high rate of false positives due to financial 
constraints. We acknowledge the limitation in assessing for some variables as binary such as 
the use of alcohol which may have affected the estimates observed. Participants were not 
asked to fast before conducting liver stiffness measurements and this may have impacted 
some of the results observed. This study however, using a readily acceptable non-invasive 
technique in the screening of liver fibrosis, provides support evidence of a high burden of 
liver fibrosis among HIV-infected persons in a resource limited setting, demonstrates 
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differences in disease distribution by locality and may provide further evidence for more 
evaluation on co-morbid conditions as risk factors of liver fibrosis other than opportunistic 
infections in the era of ART. The characterization of the risk profile for liver fibrosis by this 
study at the present time, provides valuable information that may can inform future 
intervention trials and formulate strategies for primary prevention.  
Key Conclusion  
Liver fibrosis is a common condition among HIV-infected persons in Uganda in the era of 
ART. Persons at risk are those with poorly controlled HIV infection, co-infected with viral 
hepatitis C, using tobacco products and having elevated liver transaminases. We 
recommend that the keys to reducing risk of liver fibrosis and/or liver cancer among HIV-
infected persons in Uganda may be in the use ART drugs with efficacy to achieve HIV viral 
suppression. We also recommend that the current national tobacco bill in Uganda be 
enforced and strengthened to control for the access and use of non-commercialized tobacco 
products. More studies with confirmation of hepatitis C as well as treatment of those 
infected is recommended to prevent liver fibrosis and its complications. 
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Table 1: Characteristics of HIV-infected patients presenting at the AIDC and GPC care clinics in urban and rural Uganda (2015-
2017) 
Characteristic Urban Site (1703) Rural Site (327) P-value 
Male Gender 678(40%) 125(38%) 0.647 
Mean age (SD) 44 (±10.7) 45(±10.9) 0.128 
Age Group    
<30 years 163(10%) 17(5%)  
30-39 years 311(18%) 76(23%)  
40-49 years 655(38%) 110(34%)  
50-59 years 441(26%) 88(27%)  
60-69 years 118(7%) 30(9%)  
70+ years 15(1%) 6(2%) 0.008 
Alcohol use 734(43%) 183(56%) <0.001 
Tobacco use 266(16%) 74(23%) 0.002 
Herbal Medicine use (n=2015) 345(20%) 84(27%) 0.007 
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Body Mass Index (n=2024)    
Normal weight 1005(59%) 248(76%)  
Underweight 128(8%) 41(13%)  
Overweight 381(22%) 31(10%)  
Obese 184(11%) 6(2%) <0.001 
Hepatitis B surface antigen test 
(n=1757) 
   
Positive 195(11%) 12(4%) <0.001 
Hepatitis C Antibody test 
(n=1784) 
   
Positive 28(2%) 5(2%) 0.674 
On  ART (n=2019) 1531(90%) 282(89%) 0.722 
Mean ART duration(SD) 
(n=1653) 
 
10 years(±3) 
 
4years (±6) 
 
<0.001 
Detectable HIV RNA    
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(≥1000copies/ml) (n=1595) 41(3%) 52(23%) <0.001 
Elevated liver transaminases    
Present 139(9%) 26(8%) 0.385 
Prevalence of liver fibrosis 
(n=1956) 
175(11%) 49(15%) 0.017 
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Table 2: Characteristics of 224 HIV-infected Patients attending the AIDC and GPC care clinics and identified with Liver Fibrosis by 
Fibroscan® (2015-2017) 
Characteristic Urban Clinic (134) Rural Clinic (35) p-Value 
Age (mean SD) 46(±10.7) 46(±11.1) 0.886 
Gender(n=223)    
Male 86(49%) 26(53%) 0.653 
Ever used of alcohol 78(45%) 27(55%) 0.192 
Ever used tobacco 36(21%) 19(39%) 0.009 
Ever used herbal medicines 
(n=223) 
39(22%) 13(27%) 0.486 
Body Mass Index*(n=222)    
Normal weight 103(60%) 34(69%)  
Underweight 12(7%) 9(18%)  
Overweight 43(25%) 5(10%)  
Obese 15(9%) 1(2%) 0.007 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article/doi/10.1093/ofid/ofaa483/5922323 by guest on 02 N
ovem
ber 2020
Ac
ce
pte
d M
an
us
cri
pt
Positive Hepatitis B surface 
antigen test (n=201) 
25(14%) 1(2%) 0.001 
Positive Hepatitis C antibody 
test (n=206) 
5(3%) 3(6%) 0.353 
On ART 157(90%) 41(87%) 0.551 
ART duration    
Mean years (SD)(n=181) 10.4(±3.3) 3.7 (±3.7) <0.001 
Detectable HIV viral 
load**(n=177) 
6(4%) 9(24%) <0.001 
Elevated liver 
transaminases*** 
27(17%) 3(6%) 0.057 
*World Health Organisation classification **≥1000 copies/ml.     
***AIDS Clinical Trials Group Classification. 
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Table 3: Factors Associated with Liver Fibrosis Among HIV-infected Males Patients Attending AIDC and GPC Care Clinics in urban 
and rural Uganda (2015-2017) 
 URBAN CLINIC RURAL CLINIC 
Explanatory variable Adjusted analysis p-value Adjusted analysis p-value 
 OR (CI)  OR (CI)  
Age-(10-year increase) 1.3(1.1-1.6) 0.008 1.0(0.8-1.3) 0.878 
Ever used alcohol 0.6(0.4-0.9) 0.033 0.7(0.4-1.2) 0.193 
Ever used tobacco 1.7(1.1-2.7) 0.022 1.7(1.0-2.7) 0.035 
Ever used herbal medicine 1.1(0.7-1.7) 0.754 1.1(0.6-2.0) 0.746 
Hepatitis B surfa e antigen test positive 1.1(0.6-1.9) 0.728 1.4(0.7-2.5) 0.309 
Hepatitis C antibody positive 3.1(1.1-8.6) 0.028 3.5(1.1-11.0) 0.030 
On ART 0.8(0.9-7.2) 0.840 0.9(0.1-8.5) 0.936 
Detectable HIV viral load (≥1000copies/ml) 2.3(1.2-4.6) 0.002 1.8(0.9-3.7) 0.101 
Elevated liver transaminases* 2.2(1.3-3.7) 0.002 1.4(0.7-2.5) 0.314 
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Table 4: Factors Associated with Liver Fibrosis among HIV-infected Females Patients Attending The AIDC and GPC care clinics in 
Urban and Rural Uganda (2015-2017) 
 URBAN CLINIC RURAL CLINIC 
Explanatory variable Adjusted analysis p-value Adjusted analysis p-value 
 OR (CI)  OR (CI)  
Age (10-year increase) 1.3(1.1-1.6) 0.008 1.3(1.0-1.6) 0.052 
Ever used alcohol 0.6(0.4-0.9) 0.016 0.6(0.4-1.1) 0.082 
Ever used tobacco 1.5(0.9-2.5) 0.091 2.9(1.5-5.9) 0.003 
Ever used herbal medicine 1.2(0.7-1.9) 0.474 1.0(0.6-1.8) 0.949 
Hepatitis B surface antigen positive 1.1(0.7-2.0) 0.612 0.4(0.1-1.1) 0.072 
Hepatitis C antibody positive 1.9(0.6-6.0) 0.263 2.2(0.6-9.0) 0.259 
On ART - - 0.6(0.1-4.9) 0.594 
Detectable HIV viral load (≥1000copies/ml) 1.4(0.6-3.3) 0.403 1.4(0.7-2.9) 0.404 
Elevated liver transaminases* 2.3(1.3-3.9) 0.002 2.4(1.1-5.3) 0.028 
…*AIDS Clinical Trials Group classification. 
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Figure 1 
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Figure 2 
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